Now, I’ve been watchin’ these markets for a good many years – long enough to know a sturdy prospect when I see one. And AbbVie (ABBV 0.31%) – well, she’s lookin’ right peachy. For a decade, she’s been deliverin’ returns that’d make a banker blush. Had a bit of a stumble, mind you, when that Humira patent went south. But a company that can navigate a blow like that, why, she’s got grit. And grit, friends, is worth more than all the fancy algorithms Wall Street can conjure.
Two Fine Horses in the Stable
AbbVie’s got a whole stable of medicines, treatin’ everything under the sun. But two in particular are pullin’ most of the weight: Skyrizi and Rinvoq. They’re addressin’ a heap of ailments – eczema, arthritis, the lot. Seems these two have surprised even the folks runnin’ the company, and that’s sayin’ somethin’.
They figured they’d be sellin’ about $27 billion worth of these by 2027. Then they upped that estimate by another $4 billion! Now, that’s what I call progress. And the best part? These ain’t gonna be facin’ a patent cliff anytime soon – not for at least five years. That means they’ll keep on chuggin’ along, drivin’ growth right through 2031, and likely beyond. A fella could build a respectable fortune on that alone.
Avoidin’ the Rapids
Now, every company’s got its troubles. And losin’ patent protection is about as troublesome as it gets. But AbbVie’s shown she can steer clear of the worst of it. Good news is, they ain’t got another big one loom’n on the horizon for a while. That means their earnings should keep on risin’ uninterrupted, at least until 2030.
And that gives ’em plenty of time to prepare for the next one. Smart companies don’t just sit and wait for trouble; they build new contraptions to outsmart it. AbbVie’s been doin’ just that – makin’ acquisitions, licensin’ deals, and fillin’ their pipeline with all sorts of new compounds. They’ve got dozens of programs in the works, and clinical progress will be the key. A company that invests in its future is a company worth watchin’.
A Dividend That Keeps On Givin’
Now, a company that makes a profit is good, but a company that shares that profit with its owners – that’s a company with character. AbbVie’s a “Dividend King,” meanin’ they’ve been steadily increasin’ their payouts for fifty years or more. That’s a record that’d make even the most seasoned investor tip his hat. And reinvestin’ those dividends? Why, that’s like plantin’ seeds for a future harvest. It might not seem like much at first, but over five years, it adds up. The proof is right there in their total returns – significantly higher than just the stock price appreciation.
I reckon the same will hold true through 2031. As AbbVie keeps on raisin’ those payouts, investors who stick with ’em will be handsomely rewarded. That’s another reason why I believe investin’ in this stock could pay off nicely over the next five years. It ain’t a guarantee, mind you. Nothin’ in this world is. But it’s a mighty fine prospect, and a fella could do a lot worse.
Read More
- 39th Developer Notes: 2.5th Anniversary Update
- Gold Rate Forecast
- Here’s Whats Inside the Nearly $1 Million Golden Globes Gift Bag
- The Hidden Treasure in AI Stocks: Alphabet
- TV Pilots Rejected by Networks
- The Labyrinth of JBND: Peterson’s $32M Gambit
- USD PHP PREDICTION
- 20 Must-See European Movies That Will Leave You Breathless
- The Worst Black A-List Hollywood Actors
- You Should Not Let Your Kids Watch These Cartoons
2026-01-18 15:22